Related Experiment Videos
Irinotecan-induced immune thrombocytopenia
L Bozec1, P Bierling, P Fromont
1FSMSIT, Hôpital Paul Brousse, Villejuif, France.
Summary
This study documents the first case of Irinotecan-induced immune thrombocytopenia. Severe low platelet counts in a colorectal cancer patient were linked to an IgG antibody triggered by Irinotecan chemotherapy.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Irinotecan is a key second-line chemotherapy for advanced colorectal cancer.
- Immune-mediated adverse drug reactions can complicate cancer treatment.
- Thrombocytopenia is a potential side effect of chemotherapy agents.
Observation:
- A 53-year-old patient developed severe thrombocytopenia following Irinotecan treatment.
- Platelet antibodies were investigated using indirect platelet immunofluorescence test (PIIFT) and monoclonal antibody immobilization of platelet antigen assay (MAIPA).
Findings:
- An IgG platelet antibody was detected in the patient's serum specifically in the presence of Irinotecan, not its metabolite SN-38.
- Antibody binding specificity was confirmed via CD32 MoAb blockade.
- While the exact platelet target was not identified, Glycoprotein IIb/IIIa was excluded as a binding site.
Implications:
- This case represents the first documented instance of Irinotecan-induced immune thrombocytopenia.
- Highlights the importance of considering immune mechanisms in chemotherapy-related thrombocytopenia.
- May inform clinical monitoring and management strategies for patients receiving Irinotecan.